Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy
Clin Lung Cancer
.
2024 Oct 30:S1525-7304(24)00231-6.
doi: 10.1016/j.cllc.2024.10.014.
Online ahead of print.
Authors
Dylan Fortman
1
,
Hong Wang
2
,
Robert VanderWeele
2
,
Terry Evans
2
,
James G Herman
3
,
John Rhee
2
,
Vincent Reyes
2
,
Brian McLaughlin
2
,
Antoinette Wozniak
4
,
Ashwin Somasundaram
5
,
Tarek Mekhail
6
,
Mark A Socinski
6
,
Katja Schulze
7
,
Liza C Villaruz
8
Affiliations
1
University of Pittsburgh Medical Center, Pittsburgh, PA.
2
UPMC Hillman Cancer Center, Pittsburgh, PA.
3
UPMC Hillman Cancer Center, Pittsburgh, PA; Division of Hematology-Oncology, VA Pittsburgh Health Care, Pittsburgh, PA.
4
Lung Cancer Research Foundation, New York, NY.
5
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
6
Oncology and Hematology at Orlando, AdventHealth Medical Group, Orlando, FL.
7
Genentech, South San Francisco, CA.
8
UPMC Hillman Cancer Center, Pittsburgh, PA. Electronic address: villaruzl@upmc.edu.
PMID:
39578170
DOI:
10.1016/j.cllc.2024.10.014
No abstract available
Keywords:
Immunotherapy; Immunotherapy sequencing; NSCLC.